Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.
Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.
复制标题
DOI：
10.1186/s12936-018-2185-9
复制
发表时间：
2018-02-08
期刊：
影响因子：
3
通讯作者：
González IJ
中科院分区：
文献类型：
--
作者：
Nsanzabana C;Djalle D;Guérin PJ;Ménard D;González IJ
为了限制抗疟疾耐药性的传播和影响并做出相应反应，需要加强或在一些地方建立能够实时检测和跟踪其出现和传播的监测系统。目前，抗疟疾耐药性的监测通过以下三种方法中的任何一种进行：（1）体内研究以评估药物对患者的疗效； (2) 体外/离体研究以评估寄生虫对药物的敏感性；和/或（3）分子测定，以检测与耐药性相关的经过验证的基因突变和/或基因拷贝数变化。这些方法是互补的，因为它们评估阻力的不同方面；然而，方法的标准化，特别是体外/离体和分子技术的标准化，是缺乏的。世界卫生组织制定了评估抗疟疾药物疗效的标准方案，国家疟疾控制计划使用该方案进行治疗效果研究。已经建立了东非抗疟治疗监测网络和亚马逊抗疟药耐药性监测网络等区域网络，以加强区域抗疟药耐药性监测能力。全球抗疟药物耐药性网络的建立是为了整理和提供有关抗疟药物疗效和耐药性的全球空间和时间趋势信息。虽然流行国家之间的信息交流对于监测抗疟疾耐药性至关重要，但为监测和网络活动提供可持续资金仍然具有挑战性。分子检测的技术领域正在迅速发展，并且易于使用且价格实惠的新技术正在变得可用。它们还具有对从手指刺破获得的简单血点进行高通量分析的优点。新技术与通过标准化方案和培训以及能力验证计划加强疟疾流行国家的国家参考实验室相结合，将有助于全球抗疟疾耐药性监测网络的改进和可持续性。本文的在线版本 (10.1186/s12936-018-2185-9) 包含补充材料，可供授权用户使用。
To limit the spread and impact of anti-malarial drug resistance and react accordingly, surveillance systems able to detect and track in real-time its emergence and spread need to be strengthened or in some places established. Currently, surveillance of anti-malarial drug resistance is done by any of three approaches: (1) in vivo studies to assess the efficacy of drugs in patients; (2) in vitro/ex vivo studies to evaluate parasite susceptibility to the drugs; and/or (3) molecular assays to detect validated gene mutations and/or gene copy number changes that are associated with drug resistance. These methods are complementary, as they evaluate different aspects of resistance; however, standardization of methods, especially for in vitro/ex vivo and molecular techniques, is lacking. The World Health Organization has developed a standard protocol for evaluating the efficacy of anti-malarial drugs, which is used by National Malaria Control Programmes to conduct their therapeutic efficacy studies. Regional networks, such as the East African Network for Monitoring Antimalarial Treatment and the Amazon Network for the Surveillance of Antimalarial Drug Resistance, have been set up to strengthen regional capacities for monitoring anti-malarial drug resistance. The Worldwide Antimalarial Resistance Network has been established to collate and provide global spatial and temporal trends information on the efficacy of anti-malarial drugs and resistance. While exchange of information across endemic countries is essential for monitoring anti-malarial resistance, sustainable funding for the surveillance and networking activities remains challenging. The technology landscape for molecular assays is progressing quite rapidly, and easy-to-use and affordable new techniques are becoming available. They also offer the advantage of high throughput analysis from a simple blood spots obtained from a finger prick. New technologies combined with the strengthening of national reference laboratories in malaria-endemic countries through standardized protocols and training plus the availability of a proficiency testing programme, would contribute to the improvement and sustainability of anti-malarial resistance surveillance networks worldwide. The online version of this article (10.1186/s12936-018-2185-9) contains supplementary material, which is available to authorized users.
登录
查看更多内容
DOI：
10.1016/j.ijpddr.2017.03.003
发表时间：
2017-08
期刊：
International journal for parasitology. Drugs and drug resistance
影响因子：
--
作者：
Commons RJ;Thriemer K;Humphreys G;Suay I;Sibley CH;Guerin PJ;Price RN
通讯作者：
Price RN
与柬埔寨恶性疟原虫疟疾双氢青蒿素-哌喹失败相关的遗传标记：基因型-表型关联研究。
DOI：
10.1016/s1473-3099(16)30409-1
发表时间：
2017-03
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Amato R;Lim P;Miotto O;Amaratunga C;Dek D;Pearson RD;Almagro-Garcia J;Neal AT;Sreng S;Suon S;Drury E;Jyothi D;Stalker J;Kwiatkowski DP;Fairhurst RM
通讯作者：
Fairhurst RM
影响因子：
8.1
作者：
Bhagavathula AS;Elnour AA;Shehab A
通讯作者：
Shehab A
影响因子：
15.8
作者：
Achan, Jane;Adam, Ishag;Zongo, Issaka
通讯作者：
Zongo, Issaka
影响因子：
4.9
作者：
Bhatia, Rakesh;Gautam, Ankur;Varshneya, Grish C.
通讯作者：
Varshneya, Grish C.